ARTA
RIGL icon

A.R.T. Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

A.R.T. Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,080
Closed -$20K – 227
2020
Q2 		$20K Buy
+1,080
New +$19.4K 0.03% 258
2019
Q4 		– Sell
-11,758
Closed -$220K – 1653
2019
Q3 		$220K Sell
11,758
-4,710
-29% -$97.3K 0.01% 1160
2019
Q2 		$430K Buy
16,468
+8,030
+95% +$181K 0.02% 807
2019
Q1 		$217K Sell
8,438
-9,812
-54% -$224K 0.01% 1056
2018
Q4 		$420K Buy
18,250
+56
+0.3% +$1.58K 0.03% 797
2018
Q3 		$584K Sell
18,194
-24,542
-57% -$737K 0.03% 788
2018
Q2 		$1.21M Buy
42,736
+35,156
+464% +$1.25M 0.05% 550
2018
Q1 		$268K Buy
+7,580
New +$303K 0.01% 1172
2017
Q4 		– Sell
-1,550
Closed -$39K – 1619
2017
Q3 		$39K Sell
1,550
-1,760
-53% -$42.8K ﹤0.01% 1268
2017
Q2 		$90K Buy
+3,310
New +$90.6K ﹤0.01% 1264
2016
Q3 		– Sell
-6,015
Closed -$134K – 1078
2016
Q2 		$134K Sell
6,015
-5,663
-48% -$141K 0.01% 1164
2016
Q1 		$242K Sell
11,678
-840
-7% -$20.7K 0.01% 1113
2015
Q4 		$379K Buy
12,518
+2,840
+29% +$86.1K 0.02% 974
2015
Q3 		$239K Sell
9,678
-1,510
-13% -$45.1K 0.01% 1115
2015
Q2 		$360K Buy
+11,188
New +$427K 0.01% 1119
2015
Q1 		– Sell
-2,514
Closed -$57K – 1642
2014
Q4 		$57K Buy
2,514
+122
+5% +$2.47K ﹤0.01% 1338
2014
Q3 		$46K Buy
+2,392
New +$67.6K ﹤0.01% 1247
2014
Q1 		– Sell
-16,363
Closed -$466K – 1519
2013
Q4 		$466K Buy
16,363
+4,630
+39% +$136K 0.02% 793
2013
Q3 		$420K Sell
11,733
-10,139
-46% -$370K 0.02% 848
2013
Q2 		$730K Buy
+21,872
New +$991K 0.02% 741

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

A.R.T. Advisors's RIGL Position: Q3 2020 in Review

A.R.T. Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q3 2020, closing a stake of 1,080 shares — an estimated $20K sold.

A.R.T. Advisors first reported a position in RIGL in Q2 2013 and held it in 20 quarters. The position peaked at $1.21M in Q2 2018. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2020.

  • A.R.T. Advisors reported no remaining Rigel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 1,080 Rigel Pharmaceuticals shares in Q3 2020, an estimated $20K.
  • A.R.T. Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • A.R.T. Advisors's Rigel Pharmaceuticals position peaked at $1.21M in Q2 2018.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.